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Discussion After the Speech of Ms. Veverka

QUESTION,ProfessorKing: During your speech you stated that in
some instances, $140 million is provided as an outlay for the R&D of
some of these drugs, thus establishing what would appear to be somewhat of a long recoupment period. Does the fact that larger companies
can afford this luxury limit the activity of smaller companies in this area,
and will these high costs eventually eliminate these smaller companies?
ANSWER, Ms. Veverka: No. The $140 million is looked at from a
macro perspective to illustrate what the entire industry may spend to get
one new product out. To take an individual successful product all the
way through the life cycle would result in a much smaller proportion of
the $140 million. One must also remember that the attrition rate of some
smaller companies from the cycle inflates the resulting aggregate outlay
because the R&D costs they incurred are still included in the final $140
million spent even though they may no longer be active in the production
of that particular drug. Actually one can take a new product through the
full development process for approximately $40 million.
The fact that taking a new product through the full development
stage is so expensive forces companies to be much more careful and
thoughtful in the early stages of discussion and planning when deciding
what compounds to fully develop. These hurdles have increased greatly
when compared to the potential market size of the finished product.
Companies often require that a product have $100 million in sales potential before deciding to pursue it through the development process. Unfortunately, more and more companies are taking the safer route and
only choosing to pursue the development of products that will provide
the most sales profits. However, I believe that this trend will not be sustainable over the long-term. The industry is heading into a consolidation
phase partially because of the economics of health care costs that are
beginning to change the external environment, and partially because of
the huge buildup in R&D and the sales capacity within the industry
itself.
QUESTION, Professor Edwards: How is the early planning with
respect to the pricing of pharmaceuticals done, and what are the risks
involved in this type of early price-planning? In other words, how do the
companies make judgments with respect to the pricing of
pharmaceuticals?
ANSWER, Ms. Veverka: Health care costs in the form of economic
restraints are influencing the industry. Many companies are working on
products that end up costing consumers many times more than similar
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working drugs that are priced much lower, thus causing the higherpriced drugs to be market failures. The companies that work on developing these higher-priced, same quality, drugs are working in a fundamentally unsustainable economic area.
When you examine the statistics for the U.S. pharmaceutical industry over the past several years, you can see that the unit growth in the
industry has been fairly flat and that it has been mostly a price-driven
growth. Although much of that growth is based on new products developed by innovative technology, a lot of the growth is not. It is based on
higher prices. Eventually, I believe that a price-regulatory environment
will replace the current market environment.
The regulatory market has taken hold dramatically in Japan. In a
remarkably short period of time the Japanese pharmaceutical companies
have changed their orientation from being predominantly importers of
technology from the United States and Europe, which they can exploit
on the Japanese market, to being innovators themselves. The innovation
was triggered by the steep price cutting imposed by the government.
There has been a 40% price reduction over the last eight years. The
Japanese are rapidly expanding their own development of pharmaceuticals and are beginning to market them internationally. I think they will
play a large role in the pharmaceutical market in the future.
QUESTION, Professor Shanker: The research and development
models you have proposed consist mostly of development. Does your
model have much room for basic, fundamental research which, absent a
goal, may produce some kind of beneficial result?
ANSWER, Ms. Veverka: That is an excellent observation. The information I stressed was predominantly about development. I believe
that when looking at the total R&D arena, particularly innovation, a
considerable amount of innovation comes from academia. A lot of innovation also comes from new ventures and is eventually funneled to the
major corporations who possess the knowledge and resources to truly
develop these products. My analysis is skewed towards the perspective
of the major corporations who are spending most of the development
dollars.
Referring to an earlier discussion about how one continues to stimulate true innovation, there is no clear answer. However, the area of U.S.
biotechnology is an excellent example of tremendous innovation. The
innovation there is starting to shift to the leading pharmaceutical companies themselves as the technology itself matures. The technology is now
being used as a tool for the development of small molecules.
When we conducted an attrition rate analysis of biotech companies
about three or four years ago, the attrition rate for biotech companies
was much lower than the attrition rate for other pharmaceutical companies. Today the attrition rate is rising dramatically among biotech companies. This will be an issue these companies must address in the future
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in order to ascertain their ability and resources to continue to innovate at
the scale needed in that particular area.
COMMENT, Dr. Strub: I believe that the R&D policy makers in
the United States and Europe must support basic research if we want to
be able to innovate thirty years from now. If basic research is not taking
place now, and apparently cannot be funded by industry directly, in
thirty years we will not have anything to innovate. In the past it was
mainly the United States' role to "care" for scientific progress in the last
thirty to fifty years. The United States allowed everyone free access to
the results. This has changed. Today if you publicize a result, it loses all
commercial value. That is a real problem which makes many countries
reluctant to support fundamental research.
COMMENT, Ms. Veverka: I believe that much innovation truly belongs in the academic and entrepreneurial environment because that is
where the freedom exists to innovate. More and more academic research
is being funded by grants from companies because the government is becoming less of a source for funding. From my own observations, companies who have tried to do fundamental research in-house tend to get a
poor yield on their research. These companies are better off funding
through academic institutions.
From the standpoint of management of the innovation process,
strong links with academic partners are required in order to promote the
exchange of ideas and direct research toward projects with potential
value to the company, ultimately linking the academic knowledge to the
commercialization process. However, this will not be enough to support
fundamental research.
COMMENT, Dean McNiven: Corporate grants to U.S. universities
for R&D in 1986 were approximately 5-6% of the total R&D funds in
the entire university system. In Canada the corporate grants were under
3%. Thus a majority of the funding for university research does not
come from corporations.
COMMENT, Mr. Bradley: If I'm not mistaken, a good part of the
U.S. trade deficit is in fact related to consumer products such as stereos,
televisions, cars, household appliances and boutique items. It seems to
me that innovation in the market phase for these types of products happens only briefly.
Take for example the Sony Walkman. Sony's market research department wanted to persuade the company that the Walkman would
work. They did not know which version of the Walkman would work,
so they made thirty versions, ten of which survived, and they gained a
share of the market and made money. It seems to me that this type of
marketing is not done enough, especially in light of the trade deficit problem. We have to start responding to the need for innovation in consumer
goods, and not just in a limited market like pharmaceuticals or
industrials.
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COMMENT, Ms. Veverka: With reference to the trade deficit and
the amount of U.S. innovation that has gone overseas, some nations and
industrial groups have succeeded in certain industries by focusing on the
development and the commercialization of technology.
There is clearly a need to have a balance between research, development and commercialization. I believe the United States has become
much better at recognizing that balance and also at successfully commercializing innovation.
QUESTION, Mr. Mockensturm: Two Soviets told me yesterday
that their basic premise was to encourage U.S. companies to utilize Soviet academia and research since they lack manufacturing capabilities.
For a relatively small expenditure, a U.S. firm can transfer the intellectual property rights to Soviet technology to the United States. For example, Bausch & Lomb paid $20,000 for the rights to contact lenses
invented in the Soviet Union. Do you believe that taking research overseas and conducting development at home will be widespread in the
future?
ANSWER, Ms. Veverka: Those situations are merely companies
recognizing and experimenting with the dimensions of research, as opposed to development. We also see more attention being placed on locating research near the center of technology innovation. As one begins to
develop technology and move into the commercialization process, there
is a different set of dynamics often requiring that development activity be
located close to manufacturing and process development or close to market sources.
The whole situation is industry specific and involves several issues.
From a research standpoint, where is the actual innovation occurring?
From a development standpoint, what are the key elements that need to
be managed most carefully to result in success? From a manufacturing
standpoint, is having a good yield enough? Is having the right market
characteristics to be close to the marketplace enough? The whole situation must be dealt with on an industry-by-industry basis.

